While qRT-PCR may be a more sensitive method that can identify patients whose tumours have low levels of AR expression not detected by IHC, the likelihood that such patients would benefit from androgen-directed therapies is uncertain, given that AR IHC expression thresholds for clinical response to androgen-directed therapies are relatively high, e.g., ≥10% for clinical response to enzalutamide in TNBC [8], and ≥40% for clinical response to enobosarm in HR+ breast cancer [24]. The gene discussed is AR; the disease is neoplasm.